2-naphthylamine has been researched along with aldosterone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Fujiwara, I; Ito, R; Ito, S; Kagechika, H; Kure, S; Noro, E; Parvin, R; Rainey, WE; Saito-Hakoda, A; Shimada, H; Shimizu, K; Sugawara, A; Suzuki, D; Suzuki, S; Yokoyama, A | 1 |
1 review(s) available for 2-naphthylamine and aldosterone
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
1 other study(ies) available for 2-naphthylamine and aldosterone
| Article | Year |
|---|---|
Suppressive effects of RXR agonist PA024 on adrenal CYP11B2 expression, aldosterone secretion and blood pressure.
Topics: 2-Naphthylamine; Adrenal Cortex; Aldosterone; Animals; Apoptosis; Blood Pressure; Body Weight; Calcium; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 CYP11B2; Heart Rate; Humans; Hydrocortisone; Ions; Mice, Transgenic; Nuclear Receptor Subfamily 4, Group A, Member 2; Pioglitazone; Point Mutation; Promoter Regions, Genetic; Pyrimidines; Retinoid X Receptors; RNA, Messenger; Sequence Deletion; Steroids; Thiazolidinediones | 2017 |